Plus Therapeutics Q1 2024 GAAP EPS $(0.75) Beats $(1.09) Estimate, Sales $1.677M Miss $1.688M Estimate
Portfolio Pulse from Benzinga Newsdesk
Plus Therapeutics (NASDAQ:PSTV) reported Q1 2024 GAAP EPS of $(0.75), beating the $(1.09) estimate, and sales of $1.677M, missing the $1.688M estimate. EPS improved by 63.77% YoY, and sales increased by 231.42% YoY.
May 15, 2024 | 8:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Plus Therapeutics reported better-than-expected Q1 2024 EPS of $(0.75), beating the $(1.09) estimate, and sales of $1.677M, slightly missing the $1.688M estimate. EPS improved significantly by 63.77% YoY, and sales increased by 231.42% YoY.
The significant improvement in EPS and substantial YoY sales growth are positive indicators for Plus Therapeutics. Despite the slight miss in sales estimates, the overall financial performance suggests a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100